Skip to main content
Premium Trial:

Request an Annual Quote

South Korean Research Institute of Bioscience and Biotechnology, Integrated Genomics, IDBS, Expression Analysis, GeneGo, Genedata, XDx, Ingenuity Systems

Korean Research Institute Licenses Integrated Genomics’ Software, Ergo
The South Korean Research Institute of Bioscience and Biotechnology has licensed Integrated Genomics’ Ergo software to help them analyze genomes, annotate genes, reconstruct metabolites, mine enzymatic data, and to perform comparative genomics.
Built specifically for analysis of microorganisms, Ergo integrates biological data from genomics, biochemistry, gene-expression studies, genetics, and literature.
The system’s reach extends beyond the functional analysis of DNA sequencing to an integrated platform for pattern-based analyses. It touts a host of comparative genomics tools for gene visualization in the contexts of regulation, expression data, phylogeny, chromosomal neighborhoods, and gene fusions.
Ergo contains an estimated 1,236 genomes.
Financial term so the license were not released.

IDBS Renews Participation in SAFE-BioPharma Vendor Participation Program
Electronic lab notebook provider IDBS has renewed participation in the SAFE-BioPharma Association Vendor Partner Program. SAFE creates and manages the SAFE digital identity and digital signature standard for the pharmaceutical industry.
IDBS integrated the SAFE standard in 2006 as part of its E-Workbook Suite. The company integrated the SAFE standard into its E-Workbook suite to allow scientists and others in the life sciences industry to capture, protect and exchange research data in a secure and compliant environment.

Expression Analysis, GeneGo to Ally Using 1-2-3 Workflow
GeneGo has announced that Expression Analysis will provide pathway and network analysis add-on services to its customers.
Expression Analysis, which offers microarray services and solutions for clinical trials customers, will use GeneGo’s ‘1-2-3 Workflow’ to automatically upload and normalize genomics data, compare multiple expression data sets, and ID similar and unique components, among other tasks.

Genedata Touts Data-Management, -Analysis for FRISYS
Computational biology provider Genedata has announced its collaboration with Germany’s Freiburg Initiative for System Biology. FRISYS focuses on modeling and systems analysis of signaling processes in growth and differentiation in human cells; in model photosynthetic organisms such as cyanobacteria, the moss Physcomitrella patens and Arabidopsis thaliana. In the animal modeling domain, it targets zebrafish and Caenorhabditis elegans.
FRISYS is one of four FORSYS (Forschungseinheiten der Systembiologie) Systems Biology Centers funded by the German Federal Ministry of Education and Research.
For this project, both experimental and theoretical FRISYS participants will use the Phylosopher and Expressionist solutions offered by Genedata.

XDx Selects Ingenuity Systems IPA 5.0 for Pathways Solution
Ingenuity Systems, a provider of solutions to explore, analyze, and interpret scientific data, has announced that molecular diagnostics firm XDx has licensed Ingenuity’s solution IPA 5.0.
XDx has developed a proprietary new method for noninvasively monitoring the immune system by measuring gene expression in a patient’s peripheral blood.
Ingenuity Pathways Analysis is a software application that enables researchers to model, analyze, and understand the biological and chemical systems.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more